ANAHEIM, Kalif.–(BUSINESS WIRE)–Visioneering Technologies, Inc. (VTI), ein Medizintechnikunternehmen, das Spezialkontaktlinsen entwickelt und vermarktet, wird die Ergebnisse der dreijährigen PROTECT-Studie bekannt geben – einer prospektiven, doppelbl…
Author: Business Wire
Samenvatting: Onderzoek van de nieuwe contactlens van Visioneering Technologies bewijst opmerkelijke resultaten om bijziendheid bij kinderen af te remmen
ANAHEIM, Calif.–(BUSINESS WIRE)–Visioneering Technologies, Inc. (VTI), een bedrijf gespecialiseerd in medische hulpmmiddelen dat speciale contactlenzen ontwerpt en op de markt brengt, zal de afgeronde resultaten van drie jaar onderzoek bekendmaken ui…
Riassunto: Un nuovo trial sulle lenti a contatto Visioneering Technologies mostra risultati storici nel rallentare la miopia nei bambini
ANAHEIM, Calif.–(BUSINESS WIRE)–Visioneering Technologies, Inc. (VTI), un produttore di dispositivi medici che progetta e commercializza lenti a contatto speciali, presenterà i risultati completi della sperimentazione clinica triennale PROTECT – uno …
Une nouvelle étude clinique menée par Visioneering Technologies sur des lentilles de contact révèle des résultats historiques dans le ralentissement de la myopie chez les enfants
ANAHEIM, Calif.–(BUSINESS WIRE)–Visioneering Technologies, Inc. (VTI), une société de dispositifs médicaux qui conçoit et commercialise des lentilles de contact spécialisées, va annoncer les résultats complets de l’étude PROTECT, un essai prospectif,…
Resumen: El nuevo ensayo con lentes de contacto de Visioneering Technologies arroja resultados históricos en la ralentización de la miopía infantil
ANAHEIM, Calif.–(BUSINESS WIRE)–Visioneering Technologies, Inc. (VTI), una empresa de dispositivos médicos dedicada al diseño y la comercialización de lentes de contacto especializadas, anunciará los resultados completos a tres años del estudio PROTE…
New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause
JACKSONVILLE, Fla.–(BUSINESS WIRE)–New global survey by Johnson & Johnson finds most women don’t connect eye health changes with menopause
Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $RHHBY–Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the VOYAGER study evaluating the effectiveness, durability and safety of Vabysmo® (faricimab-svo…
Visioneering Technologies' New Contact Lens Trial Shows Landmark Results in Slowing Children's Nearsightedness
ANAHEIM, Calif.–(BUSINESS WIRE)–Visioneering Technologies, Inc. (VTI), a medical device company that designs and markets specialty contact lenses, will announce completed three-year results from PROTECT, a prospective, double-masked, multinational ra…
Ray Therapeutics Awarded $8 Million CIRM Grant to Advance RTx-021 Gene Therapy for Stargardt Disease
BERKELEY, Calif.–(BUSINESS WIRE)–Ray Therapeutics (RayTx), an industry-leading clinical-stage biopharmaceutical company pioneering differentiated vision restoration therapies for those living with severe retinal degenerations, today announced it has …
GenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
OBIO’s Capital Access Advisory Program (CAAP®) Reaches Milestone with $1 Billion Raised by High-Growth Life Sciences and Health Tech Ventures
TORONTO–(BUSINESS WIRE)–OBIO® companies supported through its Capital Access Advisory Program have now collectively raised over $1 billion in capital.
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
CONCORD, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced intent to submit to the…
Azalea Vision schrijft de eerste patiënt in voor een proof-of-concept studie die een NOA (Novel Optical Aperture) voor keratoconus en presbyopie beoordeelt
GENT, België–(BUSINESS WIRE)–Azalea Vision, een Belgisch healthtech-bedrijf dat dat de eerste medisch hoogwaardige slimme contactlens tot stand brengt, maakte vandaag bekend dat het de eerste patiënt heeft ingeschreven in zijn NOA proof-of-concept st…
Azalea Vision arruola il primo paziente in uno studio di validazione volto a valutare una nuova apertura ottica per il cheratocono e la presbiopia
GAND, Belgio–(BUSINESS WIRE)–Azalea Vision, società belga del settore healthtech che sviluppa le prime lenti a contatto intelligenti per uso medico, ha annunciato oggi di avere arruolato il primo paziente del suo studio di validazione NOA. Lo studio …
Azalea Vision recrute son premier patient pour une étude de preuve de concept évaluant une nouvelle ouverture optique pour le kératocône et la presbytie
GAND, Belgique–(BUSINESS WIRE)–Azalea Vision, une entreprise belge de santé numérique qui développe la première lentille de contact intelligente à usage médical, annonce aujourd’hui avoir recruté le premier patient dans son étude de preuve de concept…
Azalea Vision incorpora al primer paciente en un estudio de prueba de factibilidad para evaluar una nueva abertura óptica para el queratocono y la presbicia
GANTE, Bélgica–(BUSINESS WIRE)–Azalea Vision, una empresa belga dedicada a la tecnología de la salud que está desarrollando la primera lente de contacto inteligente de grado médico, anunció hoy que ha incorporado al primer paciente en su estudio de p…
Azalea Vision nimmt ersten Patienten in eine Proof-of-Concept-Studie zur Bewertung einer neuartigen optischen Blende bei Keratokonus und Presbyopie auf
GHENT, Belgien–(BUSINESS WIRE)–Azalea Vision, ein belgisches Healthtech-Unternehmen, das die erste intelligente Kontaktlinse für medizinische Zwecke entwickelt, gab heute bekannt, dass es den ersten Patienten in seine NOA-Proof-of-Concept-Studie aufg…
Azalea Vision Enrolls First Patient in Proof-of-Concept Study Evaluating Novel Optical Aperture for Keratoconus and Presbyopia
GHENT, Belgium–(BUSINESS WIRE)–Azalea Vision, a Belgian healthtech company building the first medical-grade smart contact lens, today announced that it has enrolled the first patient in its NOA proof-of-concept study. The study marks the start of Aza…
Azalea Vision Enrolls First Patient in Proof-of-Concept Study Evaluating Novel Optical Aperture for Keratoconus and Presbyopia
GHENT, Belgium–(BUSINESS WIRE)–Azalea Vision, a Belgian healthtech company building the first medical-grade smart contact lens, today announced that it has enrolled the first patient in its NOA proof-of-concept study. The study marks the start of Aza…
Azalea Vision Enrolls First Patient in Proof-of-Concept Study Evaluating Novel Optical Aperture for Keratoconus and Presbyopia
GHENT, Belgium–(BUSINESS WIRE)–Azalea Vision, a Belgian healthtech company building the first medical-grade smart contact lens, today announced that it has enrolled the first patient in its NOA proof-of-concept study. The study marks the start of Aza…